58
89
Growth Score
-14 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
203438
Ultra-sensitive MRD AI-powered platform for cancer monitoring & early detection of resistance mutations.
- Rosa Ayala: Medical Director and Co-Founder
- Joaquin Martinez: President and Co-Founder
About the Company
Altum Sequencing specializes in liquid biopsy tests for cancer therapy guidance and minimal residual disease (MRD) monitoring. With a focus on biotechnology, the company offers TRACKseq, a liquid biopsy test designed for high sensitivity and cost efficiency. Altum Sequencing's innovative approach allows for the detection of one cancer cell
among millions, providing precise endpoints for clinical trials. The company's testing methods aim to improve cancer relapse detection by identifying tumor cells that conventional techniques miss. Altum Sequencing engages in research and development to advance the field of cancer diagnostics and treatment.
Women Led
